Nan Fung Group Holdings Ltd Takes Position in Kymera Therapeutics, Inc. $KYMR

Nan Fung Group Holdings Ltd purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,875 shares of the company’s stock, valued at approximately $3,540,436,000. Kymera Therapeutics comprises approximately 2.7% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 11th largest position.

Several other large investors have also recently modified their holdings of the stock. Smartleaf Asset Management LLC lifted its position in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC increased its position in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after acquiring an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at $63,000.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of recent analyst reports. Mizuho lifted their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Morgan Stanley reissued an “overweight” rating and issued a $135.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of Kymera Therapeutics in a report on Wednesday, August 5th. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $125.65.

Kymera Therapeutics Trading Up 1.0%

NASDAQ KYMR opened at $121.05 on Tuesday. The company’s 50-day moving average price is $110.13 and its 200-day moving average price is $92.46. The stock has a market cap of $10.07 billion, a PE ratio of -37.36 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12 month low of $39.84 and a 12 month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.95) EPS. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Noah Goodman sold 3,389 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the completion of the sale, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the transaction, the chief financial officer directly owned 244,883 shares in the company, valued at $28,151,749.68. The trade was a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,591,908 shares of company stock worth $386,532,863 over the last quarter. Insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.